The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) funds innovative, patient-centered clinical trials aimed at improving cancer detection, treatment, and quality of life. The program supports global collaborations between academic institutions and non-profit organizations to advance meaningful cancer research.
Eligibility Criteria:
-
Applicants must represent an academic institution or not-for-profit organization.
-
Projects must be interventional clinical trials (Phase I–III) with active patient partner involvement in study design.
-
Studies focused on early detection and intervention in pre-cancerous changes may be considered at the pre-clinical validation stage.
-
Basic research, Phase IV trials, and observational studies are not eligible.
-
Projects involving immunotherapies should be discussed with RTFCCR prior to application.
Funding Details:
-
Funding supports Phase I–III interventional clinical trials that are innovative, patient-centered, and globally relevant.
-
Pre-application grants are available for patient partners contributing to project design.
-
The final funding decision is made by the Rising Tide Foundation Board of Directors based on scientific merit, innovation, and alignment with strategic priorities.
Deadline:
-
Upcoming Letter of Intent (LOI) deadline: November 23, 2025
-
Additional LOI deadlines: March 9, 2026; May 29, 2026; November 23, 2026
Where to go for further information: